Perspective Therapeutics (NYSE:CATX) Earns “Overweight” Rating from Cantor Fitzgerald

Perspective Therapeutics (NYSE:CATX)‘s stock had its “overweight” rating reaffirmed by Cantor Fitzgerald in a report released on Tuesday, Benzinga reports.

Several other research firms have also recently weighed in on CATX. Lifesci Capital reissued an “outperform” rating on shares of Perspective Therapeutics in a report on Monday, May 6th. B. Riley increased their price target on Perspective Therapeutics from $12.00 to $17.00 and gave the company a “buy” rating in a report on Tuesday, April 9th. Oppenheimer reissued an “outperform” rating and set a $15.00 price target (up from $12.00) on shares of Perspective Therapeutics in a report on Monday, April 1st. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $30.00 price target on shares of Perspective Therapeutics in a report on Friday. Six research analysts have rated the stock with a buy rating, According to MarketBeat, Perspective Therapeutics presently has an average rating of “Buy” and an average price target of $19.00.

Perspective Therapeutics Price Performance

CATX stock traded up $0.12 during midday trading on Tuesday, hitting $10.46. The company’s stock had a trading volume of 157,859 shares, compared to its average volume of 476,664. Perspective Therapeutics has a 12 month low of $2.05 and a 12 month high of $19.05. The company has a quick ratio of 12.98, a current ratio of 12.98 and a debt-to-equity ratio of 0.01.

Perspective Therapeutics (NYSE:CATX) last released its quarterly earnings data on Wednesday, May 15th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.10. The business had revenue of $0.33 million for the quarter. Perspective Therapeutics had a negative return on equity of 46.38% and a negative net margin of 302.70%. Research analysts expect that Perspective Therapeutics will post -0.11 earnings per share for the current fiscal year.

Insider Transactions at Perspective Therapeutics

In other Perspective Therapeutics news, CEO Johan M. Spoor purchased 10,000 shares of the business’s stock in a transaction on Thursday, June 13th. The stock was acquired at an average price of $11.70 per share, for a total transaction of $117,000.00. Following the purchase, the chief executive officer now owns 13,757 shares of the company’s stock, valued at approximately $160,956.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Robert F. Williamson III acquired 3,003 shares of the company’s stock in a transaction on Wednesday, May 29th. The stock was acquired at an average price of $13.30 per share, with a total value of $39,939.90. Following the acquisition, the director now directly owns 36,879 shares of the company’s stock, valued at $490,490.70. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Johan M. Spoor acquired 10,000 shares of the company’s stock in a transaction on Thursday, June 13th. The shares were bought at an average cost of $11.70 per share, with a total value of $117,000.00. Following the acquisition, the chief executive officer now directly owns 13,757 shares in the company, valued at $160,956.90. The disclosure for this purchase can be found here. Insiders purchased 24,427 shares of company stock worth $317,830 in the last three months. Corporate insiders own 3.52% of the company’s stock.

Institutional Trading of Perspective Therapeutics

A number of large investors have recently made changes to their positions in the business. ZWJ Investment Counsel Inc. purchased a new position in Perspective Therapeutics in the first quarter worth about $26,000. Simplicity Wealth LLC purchased a new position in shares of Perspective Therapeutics in the 1st quarter worth approximately $40,000. Bleakley Financial Group LLC purchased a new position in shares of Perspective Therapeutics in the 1st quarter worth approximately $40,000. RIA Advisory Group LLC increased its position in shares of Perspective Therapeutics by 1,313.4% during the 1st quarter. RIA Advisory Group LLC now owns 106,853 shares of the company’s stock valued at $127,000 after purchasing an additional 99,293 shares during the last quarter. Finally, Virtu Financial LLC purchased a new stake in Perspective Therapeutics during the 1st quarter valued at $138,000. 54.66% of the stock is currently owned by institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.